Mario Mezler

Prof. Dr. Mario Mezler

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MMMario Mezler
Mario Mezler
SBS Barghorn
S Barghorn
HSH Schoemaker
H Schoemaker
GGG Gross
G Gross
VNV Nimmrich
V Nimmrich
BACKGROUND AND PURPOSEβ‐amyloid (Aβ) oligomers have been implicated in the early pathophysiology of Alzheimer's disease (AD). While the precise nature of the molecular target has not been fully revealed, a number of studies have indicated that Aβ oligomers modulate neuron‐specific ion channels. We recently provided evidence that Aβ oligomers suppress isolated P/Q‐type calcium currents in cultured nerve cells. Using a heterologous expression system, we aimed to prove a direct effect on the membrane channel mediating such current.EXPERIMENTAL APPROACHThe effects of a synthetically generated Aβ oligomer, Aβ globulomer, were investigated on P/Q‐type currents recorded fromXenopus laevisoocytes expressing the full P/Q‐type calcium channel or the pore‐forming subunit only. We also examined the effects of Aβ globulomer on recombinant NMDA receptor currents. Finally, we compared the modulation by Aβ globulomer with that induced by a synthetic monomeric Aβ.KEY RESULTSAβ globulomer directly and dose‐dependently modulated P/Q‐type calcium channels. A leftward shift of the current‐voltage curve indicated that the threshold for channel opening was reduced. The effect of Aβ globulomer was also present when only the α1A subunit of the normally tripartite channel was expressed. In contrast, the monomeric Aβ had no effect on P/Q current. Also globulomer Aβ had no effect on glutamate‐induced NMDA currents.CONCLUSIONS AND IMPLICATIONSThe α1A subunit of the P/Q‐type calcium channel is directly modulated by oligomeric Aβ. Threshold reduction as well as an increase in current at synaptic terminals may facilitate vesicle release and could trigger excitotoxic events in the brains of patients with AD.

11 September 2020 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
DYDong Ye
Dong Ye
AHAnna Harder
Anna Harder
ZFZhizhou Fang
Zhizhou Fang
MWManuel Weinheimer
Manuel Weinheimer
LLLoic Laplanche
Loic Laplanche
MMMario Mezler
Mario Mezler

28 September 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Mirko KoziolekMirko Koziolek
Mirko Koziolek
PAPatrick Augustijns
Patrick Augustijns
CBConstantin Berger
Constantin Berger
Rodrigo CristofolettiRodrigo Cristofoletti
Rodrigo Cristofoletti
DDDavid Dahlgren
David Dahlgren
JDJennifer Dressman
Jennifer Dressman
Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed.

29 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMAxel Meyer
Axel Meyer
TFThomas Feldsien
Thomas Feldsien
MMMario Mezler
Mario Mezler
CUChristopher Untucht
Christopher Untucht
RVRamakrishna Venugopalan
Ramakrishna Venugopalan
DLDidier R. Lefebvre
Didier R. Lefebvre
The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS). Because of this barrier there is still a huge unmet need for the treatment of these diseases, despite years of research efforts across the pharmaceutical industry. Novel therapeutic entities, such as gene therapy and degradomers, have become increasingly popular in recent years, but have not been the focus for CNS indications so far. To unfold their full potential for the treatment of CNS diseases, these therapeutic entities will most likely have to rely on innovative delivery technologies. Here we will describe and assess approaches, both invasive and non-invasive, that can enable, or at least increase, the probability of a successful drug development of such novel therapeutics for CNS indications.

22 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PMPatricia Muschong
Patricia Muschong
KAKhader Awwad
Khader Awwad
EPEdward Price
Edward Price
MMMario Mezler
Mario Mezler
MWManuel Weinheimer
Manuel Weinheimer
Current drug development tends towards complex chemical molecules, referred to as “beyond rule of five” (bRo5) compounds, which often exhibit challenging physicochemical properties. Measuring Caco-2 permeability of those compounds is difficult due to technical limitations, including poor recovery and detection sensitivity. We implemented a novel assay, with optimized incubation and analytics, to measure permeability close to equilibrium. In this setup an appropriate characterization of permeability for bRo5 compounds is achievable. This equilibrated Caco-2 assay was verified with respect to data validity, compound recovery, and in vitro to in vivo correlation for human absorption. Compared to a standard assay, it demonstrated comparable performance in predicting the human fraction absorbed (fa) for reference compounds. The equilibrated assay also successfully characterized the permeability of more than 90% of the compounds analyzed, the majority of which were bRo5 (68%). These compounds could not be measured using the standard assay. Permeability and efflux ratio (ER) were highly predictive for in vivo absorption for a large set of internal bRo5 compounds. Reference cut-offs enabled the correct classification of high, moderate, and low absorption. This optimized equilibrated Caco-2 assay closes the gap for a high-throughput cellular permeability method in the bRo5 chemical space.

24 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DYDong Ye
Dong Ye
ÁMÁlvaro López Mármol
Álvaro López Mármol
VLVerena Lenz
Verena Lenz
PMPatricia Muschong
Patricia Muschong
AWAnita Wilhelm-Alkubaisi
Anita Wilhelm-Alkubaisi
MMMario Mezler
Mario Mezler
The poor solubility and permeability of compounds beyond Lipinski’s Rule of Five (bRo5) are major challenges for cell-based permeability assays. Due to their incompatibility with gastrointestinal components in biorelevant media, the exploration of important questions addressing food effects is limited. Thus, we established a robust mucin-protected Caco-2 assay to allow the assessment of drug permeation in complex biorelevant media. To do that, the assay conditions were first optimized with dependence of the concentration of porcine mucin added to the cells. Mucin-specific effects on drug permeability were evaluated by analyzing cell permeability values for 15 reference drugs (BCS class I–IV). Secondly, a sigmoidal relationship between mucin-dependent permeability and fraction absorbed in human (fa) was established. A case study with venetoclax (BCS class IV) was performed to investigate the impact of medium complexity and the prandial state on drug permeation. Luminal fluids obtained from the tiny-TIM system showed a higher solubilization capacity for venetoclax, and a better read-out for the drug permeability, as compared to FaSSIF or FeSSIF media. In conclusion, the mucin-protected Caco-2 assay combined with biorelevant media improves the mechanistic understanding of drug permeation and addresses complex biopharmaceutical questions, such as food effects on oral drug absorption.